Abstract:Chemotherapy is the preferred treatment for advanced ovarian cancer, but the 5-year survival rate remains low partly because of the development of drug resistance. Although it has been reported that X-linked inhibitor of apoptosis (XIAP) causes more severe chemoresistance in ovarian cancer cells and is highly expressed in chemoresistant ovarian cancer, the molecular mechanism underlying this dysregulation is unknown. The purpose of this study was to identify microRNAs (miRNAs) that bind to the 3' untranslated region (3'UTR) of XIAP and have a role in chemoresistance in ovarian cancer. Using in silico analysis and literature review, a panel of miRNAs dysregulated in chemoresistant ovarian cancer was generated from hundreds of miRNAs that were predicted to target the XIAP 3'UTR. Using a dual luciferase reporter assay and cellular co-transfection of a miRNA expression vector and a luciferase reporter fused to the XIAP 3'UTR cognate miRNA binding site, we identified three miRNAs of which miR-142-5p had the greatest inhibitory effect. We found that overexpression of miR-142-5p suppressed XIAP expression by binding to its 3'UTR in OVCAR3 and SKOV3 cells. Using a chemosensitivity assay, we found that in OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells, overexpression or inhibition of miR-142-5p increased or suppressed their sensitivities to cisplatin respectively. In contrast, introducing XIAP without a 3'UTR counteracted the effect of overexpressed miR-142-5p on cisplatin-induced apoptosis in OVCAR3 ovarian cancer cells. Furthermore, we found a negative correlation between miR-142-5p expression and XIAP protein levels in clinical samples from patients with EOC. Using clinical and miRNA expression data of more than 200 ovarian cancer patients treated with platinum-based chemotherapy from The Cancer Genome Atlas (TCGA) database, we found ovarian cancer patients with higher expression levels of miR-142-5p had longer median progression-free survival as compared to patients with lower miR-142-5p levels. We demonstrated that miR-142-5p also targeted four other anti-apoptotic genes, baculoviral IAP repeat-containing 3 (BIRC3), B-cell lymphoma-2 (BCL2), BCL2 like 2 (BCL2L2), and myeloid cell leukemia sequence 1 (MCL1) specifically. Transcriptome sequencing shed light on the essential apoptosis-related pathway in which miR-142-5p may be involved. To conclude, our findings illustrate that miR-142-5p sensitizes ovarian cancer cells to cisplatin-induced apoptosis by targeting multiple anti-apoptotic genes including XIAP, and may also suggest the therapeutic potential of miR-142-5p in ovarian cancer treatment.

MiR-490-3p Sensitizes Ovarian Cancer Cells to Cisplatin by Directly Targeting ABCC2.

MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.

Overexpression Of Mir-199a-5p Confers Cisplatin Resistance In Ovarian Cancer Cells By Regulating Gsk-3 Beta

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.

Mir-509-3p Enhances Platinum Drug Sensitivity in Ovarian Cancer.

Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85

MiR-34a-5p/PD-L1 Axis Regulates Cisplatin Chemoresistance of Ovarian Cancer Cells.

MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway

miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

Mir‑210‑3p Regulates Cell Growth and Affects Cisplatin Sensitivity in Human Ovarian Cancer Cells Via Targeting E2F3.

Mir-142-5p Enhances Cisplatin-Induced Apoptosis in Ovarian Cancer Cells by Targeting Multiple Anti-Apoptotic Genes.

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A

MiR-624-5p Enhances Cell Resistance Against Cisplatin Via PDGFRA/Stat3/PI3K Axis in Ovarian Cancer

Microrna-133b Targets Glutathione S-Transferase Pi Expression To Increase Ovarian Cancer Cell Sensitivity To Chemotherapy Drugs

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine

Mir-378A-3p Sensitizes Ovarian Cancer Cells to Cisplatin Through Targeting MAPK1/GRB2.

Microrna184 Reverses Cisplatin Resistance in Human Ovarian Cancer Cells by Regulating the Phosphatidylinositol-3-Kinase (pi3k)/protein Kinase B (AKT) Signaling Pathway

MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1